Suppr超能文献

线粒体突变与线粒体表观遗传学:聚焦于调控乳腺癌中氧化应激诱导反应。

Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers.

机构信息

The First Affiliated Hospital of Zhengzhou University, 1 Jianshedong Street, Zhengzhou, 450052, China; Institue for Regenerative Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2 Trubetskaya Street, Moscow, 119991, Russia.

The First Affiliated Hospital of Zhengzhou University, 1 Jianshedong Street, Zhengzhou, 450052, China.

出版信息

Semin Cancer Biol. 2022 Aug;83:556-569. doi: 10.1016/j.semcancer.2020.09.012. Epub 2020 Oct 6.

Abstract

Epigenetic regulation of mitochondrial DNA (mtDNA) is an emerging and fast-developing field of research. Compared to regulation of nucler DNA, mechanisms of mtDNA epigenetic regulation (mitoepigenetics) remain less investigated. However, mitochondrial signaling directs various vital intracellular processes including aerobic respiration, apoptosis, cell proliferation and survival, nucleic acid synthesis, and oxidative stress. The later process and associated mismanagement of reactive oxygen species (ROS) cascade were associated with cancer progression. It has been demonstrated that cancer cells contain ROS/oxidative stress-mediated defects in mtDNA repair system and mitochondrial nucleoid protection. Furthermore, mtDNA is vulnerable to damage caused by somatic mutations, resulting in the dysfunction of the mitochondrial respiratory chain and energy production, which fosters further generation of ROS and promotes oncogenicity. Mitochondrial proteins are encoded by the collective mitochondrial genome that comprises both nuclear and mitochondrial genomes coupled by crosstalk. Recent reports determined the defects in the collective mitochondrial genome that are conducive to breast cancer initiation and progression. Mutational damage to mtDNA, as well as its overproliferation and deletions, were reported to alter the nuclear epigenetic landscape. Unbalanced mitoepigenetics and adverse regulation of oxidative phosphorylation (OXPHOS) can efficiently facilitate cancer cell survival. Accordingly, several mitochondria-targeting therapeutic agents (biguanides, OXPHOS inhibitors, vitamin-E analogues, and antibiotic bedaquiline) were suggested for future clinical trials in breast cancer patients. However, crosstalk mechanisms between altered mitoepigenetics and cancer-associated mtDNA mutations remain largely unclear. Hence, mtDNA mutations and epigenetic modifications could be considered as potential molecular markers for early diagnosis and targeted therapy of breast cancer. This review discusses the role of mitoepigenetic regulation in cancer cells and potential employment of mtDNA modifications as novel anti-cancer targets.

摘要

线粒体 DNA(mtDNA)的表观遗传调控是一个新兴且快速发展的研究领域。与核 DNA 的调控相比,mtDNA 表观遗传调控(mitoepigenetics)的机制仍较少被研究。然而,线粒体信号传导指导着各种重要的细胞内过程,包括需氧呼吸、细胞凋亡、细胞增殖和存活、核酸合成以及氧化应激。后一过程以及相关的活性氧(ROS)级联的错误管理与癌症进展有关。已经证明,癌细胞包含 ROS/氧化应激介导的 mtDNA 修复系统和线粒体核区保护缺陷。此外,mtDNA 容易受到体细胞突变引起的损伤,导致线粒体呼吸链和能量产生的功能障碍,这促进了 ROS 的进一步产生,并促进了致癌性。线粒体蛋白由包含核基因组和线粒体基因组的线粒体基因组集体编码,并通过串扰相互作用。最近的报告确定了有利于乳腺癌发生和进展的集体线粒体基因组缺陷。mtDNA 的突变损伤,以及其过度增殖和缺失,据报道会改变核表观遗传景观。不平衡的 mitoepigenetics 和氧化磷酸化(OXPHOS)的不利调节可以有效地促进癌细胞存活。因此,建议几种针对线粒体的治疗药物(双胍类药物、OXPHOS 抑制剂、维生素 E 类似物和抗生素 bedaquiline)用于未来乳腺癌患者的临床试验。然而,改变的 mitoepigenetics 与癌症相关的 mtDNA 突变之间的串扰机制在很大程度上仍不清楚。因此,mtDNA 突变和表观遗传修饰可以被认为是乳腺癌早期诊断和靶向治疗的潜在分子标志物。本综述讨论了 mitoepigenetic 调节在癌细胞中的作用以及 mtDNA 修饰作为新型抗癌靶标的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验